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Summary The biological consequence of the binding ofcis-dichlorodiammineplatinum(II) (cis-DDP) to serum
protein as well as to cellular components in general, was studied on human NHIK 3025 cells in vitro. As
expected, we found that the cytotoxicity of cis-DDP was lost by binding to serum protein, and that
protein-bound platinum was impermeable to the cells. As we have previously shown that electropermeabilisa-
tion may transiently increase the influx of cis-DDP, we applied this technique in an attempt to increase the
efflux of cis-DDP or any other cytotoxic intermediates. Our data demonstrate that if cells are electro-
permeabilised shortly after treatment with cis-DDP, cell survival increased. This indicates that cis-DDP in an
active form is released from the cells; furthermore, the plasma membrane represents a barrier against efflux, as
it has also been shown to be against influx of active cis-DDP. Thus, our data are consistent with the idea that
there must be an intracellular pool of either cis-DDP, or some biologically active intermediates, in cells treated
with this drug. Additionally, our data indicate that the binding rate of cis-DDP to biological molecules is
much quicker intracellularly than in the extracellular environment: We found the biological half-life at 37°C to
be about 2.1 h in human serum and about 11 min inside our cells.
It is widely accepted that lethal cellular damage by cis-DDP
is primarily caused by reactions involving binding to nuclear
DNA (Roberts & Fraval, 1980; Zwelling & Kohn, 1979). To
complete these reactions, cis-DDP in an active form must
enter the cells and react with DNA. However, it is known
that cis-DDP may also bind to protein and other molecules
and thereby become biologically inactivated (Melvik & Pet-
tersen, 1987; Gormley et al., 1979; Dedon & Borch, 1987;
Litterst et al., 1986; Goel et al., 1990; Meijer et al., 1990).
Thus, the kinetics of cis-DDP binding is complex, involving
numerous extracellular and intracellular reactions. Further-
more, uptake through the plasma membrane is a rate-limiting
factor in the cytotoxicity induced by cis-DDP (Melvik et al.,
1986; Dornish et al., 1986).
In the present study we have performed experiments in an
attempt to demonstrate the presence as well as the rate of
reduction of, an intracellular pool of active drug after treat-
ment with cis-DDP. We have focused on the extracellular as
well as intracellular binding rate of cis-DDP to biological
molecules. To study binding of cis-DDP to macromolecules
inside the cells we have used electropermeabilisation, which
renders the cell membrane transiently permeable to cis-DDP
(Melvik et al., 1986), at various times after a short pulse with
the drug. Our data show that this method may increase the
efflux of drug as well as increase cell survivial when cells are
electropermeabilised shortly after exposure to cis-DDP. Thus,
our data indicate the presence of an intracellular pool of
active drug for a short time period following drug treatment.
Moreover, the efflux of active drug from the cells is inhibited
by the cell membrane.
1969; Oftebro & Nordbye, 1969) were used. The cells were
routinely grown as a monolayer, at 37°C in medium E2a
(Puck et al., 1957) containing 20% human serum prepared in
the laboratory and 10% horse serum (Gibco). In order to
maintain cells in continuous exponential growth, the cell
cultures were trypsinised (0.25% trypsin, Difco 1:250) and
recultured three times a week (Pettersen et al., 1977). Cells
were routinely recultured the day before use in experiments.
Cell survival
The cell inactivating effect of cis-DDP was measured as loss
of colony-forming ability of cells treated with cis-DDP. The
cells were trypsinised and seeded as single cells into 6 cm
Falcon plastic Petri dishes with 5 ml medium. The cell
number was adjusted to give, after treatment, about 150
colonies per dish. The cells were incubated for a total of
12-14 days with a medium change on day 6, and thereafter
fixed in ethanol and stained with methylene blue. Only col-
onies containing more than 40 cells were counted. Each
observation was calculated as the mean of five replicate
dishes.
Electropermeabilisation requires that cells be in suspen-
sion, therefore, for experiments involving electropermeabilisa-
tion, cells were treated in suspension. There was, however, no
significant differences in cell survival for NHIK 3025 cells
treated with cis-DDP in suspension as compared to treatment
of attached cells (Melvik et al., 1986). Treatment was stopped
by removing cis-DDP by centrifugation (350 g in 5 min) with
an immediate substitution to fresh medium. Treatment was
performed either at room temperature (20-26°C) or at 37°C.
Materials and methods Atomic absorption spectroscopy
Cells and cell culturing technique
Cells of the established cell line NHIK 3025, derived from
human uterine cervix carcinoma in situ (Nordbye & Oftebro,
After treatment with cis-DDP the cells were centrifuged and
washed once in fresh medium before they were dissolved in
60jil 16 N HNO3. The day after, 60 LIH20 was added to
each sample. The amount of cellular-bound platinum was
measured using a Varian SpectrAA-30 atomic absorption
spectrometer fitted with a GTA-96 graphite tube atomiser.
Instrument control and data acquisition was by Varian DS-
15 Data Station using Varian Atomic Absorption Software.
The atomic absorption signal was measured in 30 gAl aliquotes
with a platinum lamp at 265.9 nm. Automatic background
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correction with a modulated duterium lamp was utilised. The
amount of Pt was calculated from a calibration curve run
immediately before samples. Each experimental point
represents the mean of three parallel measurements.
Electropermeabilisation
The apparatus and method for electropermeabilisation was
essentially as previously described (Gordon & Seglen, 1982;
Melvik et al., (1986). Briefly, 2 ml aliquotes of cell suspen-
sions were placed in a square-bottomed (1 x 1 cm) Perspex
chamber; two of the opposing walls were flat stainless steel
electrodes. The electrodes were connected to a 1.2 ;F
capacitor connected to a 2 kV power supply. The capacitor
was charged by the power supply and discharged through the
circuit containing the electrode chamber. Five consecutive
discharges were given at intervals of about 3 sec, and the
time constant of each discharge through the cell suspension
was found to be about 45,.sec.
Ultrafiltration ofprotein-boundplatinum
A suspension of 10 gsM cis-DDP dissolved in E2a was stored
at 37°C in the dark before 1 ml aliquotes were placed in
MPS-1 filters (Amicon, USA) and centrifuged at 10°C for
25 min at 1100 g. The concentration of Pt in the ultrafiltrate
was measured by atomic absorption spectroscopy.
Drugs
Cis-dichlorodiammineplatinum(II) (cis-DDP) was from Far-
mitalia Carlo Erba (Barcelona, Spain). Cis-DDP was first
dissolved in glycozole (Rofstad et al., 1980) as a stable stock
solution with a concentration of 1000 ILM before it was
further diluted in the growth medium and added to the cells.
Results
Due to binding of cis-DDP to protein, the biological
effectivity of this drug may be of short duration when dis-
solved in serum or serum-containing medium. To charac-
terise this parameter in our cell culture we performed the
experiment shown in Figure 1. While panel a in Figure 1
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Figure 1 Cell survival ofexponentially growing NHIK 3025 cells
after treatment with cis-DDP. a, Cells were treated for 2 h with
cis-DDP immediately after the drug was dissolved in medium
E2a. Different symbols show different experiments. The straight
line was fitted by the method of least squares, b, cells were
treated for 2 h (@,A) or 6 days (V (one point)) with IOjM
cis-DDP. The abscissa shows the time from dilution of cis-DDP
in medium E2a (0) or human serum (A) (i.e. time 0) until start
of treatment. During this time medium E2a or serum was stored
at 37°C. The dotted line shows how data in b was used in a to
calculate the 'effective concentration' of cis-DDP still remaining
at different times after the solutions were prepared. The standard
error (S.E.) is indicated when exceeding the symbol size.
shows the surviving fraction of cells treated with cis-DDP
added immediately after the drug was dissolved in the
medium, panel lb shows the surviving fraction of cells which
had medium with cis-DDP (10pM) added to the cells at
various times (abscissa) after the drug was dissolved (in
either medium or serum). From panel b in Figure 1 the
inactivating potential of cis-DDP decreases with the time it is
dissolved in both serum and in medium E2a.
For cis-DDP concentrations above 2 M in panel la, ex-
perimental points are well fitted by a straight line (slope:
Do=2.8 ± 0.2pLM (S.E.).
By combining the data in Figure lb and the straight line
fitting in Figure la, as indicated by the dashed line in Figure
1, one finds the concentration of cis-DDP (from panel la)
which, if the drug is added to the cells immediately after it is
dissolved, would give the same cell inactivating effect as that
observed in panel lb. Thus, for each experimental point in
panel lb, we can relate the biological effects to an estimated
'effective concentration' of cis-DDP. In this context, by
'effective concentration' we mean the concentration of cis-
DDP having the same potential for inactivating cells immed-
iately after the drug is dissolved in medium, as the current
solution has after storage.
Figure 2 shows the effective concentration as determined
for the experimental points in Figure lb relative to the values
obtained at time 0. The data are fitted with exponential
functions indicating that the effective concentration of cis-
DDP decreases with a half-life (t1) of 2.1 ± 0.03(S.E.) h in
serum and 6.0 ± 0.05(S.E.) h in medium E2a. Thus, t1 is
about three times longer in medium than in serum. Since the
concentration of serum components are higher by a factor of
three in serum as compared to medium this points to serum
components as responsible for the reduced effective concent-
ration of cis-DDP.
In Figure 2 the relative amount of Pt remaining in E2a
medium after ultrafiltration, i.e. after removal of protein and
protein-bound Pt (MW>30,000 dalton) at different times
after 10 LM cis-DDP was diluted in the growth medium
(open circles) is also shown. The data show that the remain-
ing amount of Pt in the ultrafiltrate decreases with a similar
initial rate-constant as the effective concentration of cis-DDP
in the E2a medium (6.8 ± 0.1 h).
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Figure 2 The relative effective concentration of cis-DDP, cal-
culated from data in Figure 1 as explained in the text, still
remaining in medium E2a (0) or serum (A) at different times
after the solutions were prepared and stored at 37°C. The amount
of Pt in the ultrafiltrate was also measured after dissolving cis-
DDP in the E2a medium (V). The effective concentration of
cis-DDP decreased exponentially and t4 in serum was calculated
to 2.1 ± 0.03 h and in medium E2a to 6.0 ± 0.05 h (S.E.). The
half-life of the amount of ultrafilterable Pt was calculated to
6.8 ± 0.1 h. Symbols for the relative effective concentration of
cis-DDP are shown with S.E.262 J.E. MELVIK et al.
The temperature dependence of the loss ofcytotoxic poten-
tial of cis-DDP in the presence or absence of serum com-
ponents was studied in a separate experiment (Figure 3). A
concentration of 1000 ttM of cis-DDP was made up in either
glycozole (an isotonic salt solution), medium E2a, or whole
serum and stored at 4°C, 22°C or 37°C for 24 h before the
solutions were diluted 1:100 with medium E2a and added to
the cells for 2 h. In Figure 3 both the cell survival (panel a)
and the amount of cell-associated Pt (panel b) are shown.
When dissolved in glycozole, which contains no serum, cell
survival was not affected by the duration of storage of cis-
DDP before cell treatment started, irrespective of the storage
temperature. In medium E2a as well as in serum, the effect
on cell survival as well as the amount of cell-associated Pt,
decreased with storage time at all temperatures tested, but
the rate of decrease in effect was clearly temperature depen-
dent.
To try to shed some light on the rate of cis-DDP binding
to cellular macromolecules, we have made use of our
previous observation that the use of electrical discharges to
cells renders the cell membrane transiently permeable to cis-
DDP without affecting normal cell growth (Melvik et al.,
1986). In Figure 4 cell survival is shown for NHIK 3025 cells
treated with a high concentration of cis-DDP (filled symbols)
for 25 min before the drug was removed, and the cells were
exposed to electrical discharges (electropermeabilisation).
What we will hereafter denote a 'standard discharge treat-
ment', consisted of five consecutive, single discharges given
over a period of 15 s. The cells received one such standard
discharge treatment about 3 min after cis-DDP was removed
(which was the quickest we could manage), and thereafter the
procedure was repeated at intervals of 20 min. The data in
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Figure 3 a, Cell survival of exponentially growing NHIK 3025
cells after treatment with cis-DDP for 2 h. Cis-DDP was dis-
solved in serum (A), medium E2a (0) or glycozole (O) to a
concentration of 1,000 M and stored at 4'C, 22°C or 37°C for
24 h before further dilution in medium E2a to 10 JiM immediately
followed by cell treatment. In a separate experiment the drug was
dissolved in glycozole and immediately (without storage) diluted
to 10 JiM in medium E2a followed by cell treatment (0). S.E. did
not exceed the size of the symbols. b, The amount of cell-
associated Pt measured by flameless atomic absorption spectro-
scopy in NHIK 3025 cells immediately following the treatment as
described in a.
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Figure 4 show cell survival as a function of the number of
standard discharge treatments received by the cells both at
37°C and at room temperature. Cell survival is also shown
for cells treated with electrical discharges alone, i.e. without
treatment with cis-DDP (open symbols). For these cells only
a very slight effect on cell survival is seen, except for cells
given a maximum of four standard discharge treatments at
room temperature, where only 10% of the cells retained their
colony-forming ability. For cells treated with cis-DDP, the
data have been normalised relative to the effect of the elect-
ropermeabilisation procedure itself, such that the drug effect
alone is shown. At both temperatures cell survival was higher
when the cells were electropermeabilised 3 min after the end
of cis-DDP treatment compared to cells not electroperme-
abilised. This effect is more clearly pronounced at room
temperature than at 37°C where only a small increase in cell
survival was seen. Repeating the electropermeabilisations at
20 min intervals resulted in no further increase in cell sur-
vival.
We have recently found that release of cell-associated Pt
from NHIK 3025 cells after exposure to cis-DDP is relatively
slow with time (Melvik et al., 1992); 2 h after a 25 min
exposure the total amount of cell-associated Pt was lowered
by only about 10%. The increase in cell survival observed
after electropermeabilisation can therefore be explained by
the loss of either cis-DDP or some cytotoxic intermediates
from the cells due to the increased permeability of the plasma
membrane caused by the electropermeabilisation. With this in
mind we performed a similar experiment where we subjected
the cells to only one standard discharge treatment but varied
the time between the end of the 25 min cis-DDP treatment
and the start of electropermeabilisation. From Figure 5 one
can see that survival of cells subjected to electropermeabilisa-
tion at room temperature decreased with increasing time
interval from the end of the cis-DDP treatment to the start
of the electropermeabilisation. When cells were subjected to
electropermeabilisation later than 80 min after cis-DDP was
removed, the cell survival was similar to that of cells treated
with cis-DDP without electropermeabilisation. Thus, for
treatment occurring at room temperature it seems to take up
to 80 min before cis-DDP, i.e. in an active form, can no
longer be released from the cells by the electropermeabilisa-
tion procedure.
In order to compare the time course of the intracellular
binding of cis-DDP versus the extracellular loss of drug
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Figure 4 Cell survival of NHIK 3025 cells after treatment with
0-4 standard discharge treatments (each consisting of five con-
secutive discharges). The cells were treated at 37°C with (A) or
without (A) 130 tM cis-DDP, or at room temperature with (0)
or without (0) 400jiM cis-DDP for 25 min. The first treatment
with electrical discharges was given 5 min after ended drug treat-
ment, thereafter each additional treatment occurred at intervals
of 20 min. For cells treated with cis-DDP each point was nor-
malised relative to effect of the electrical discharge treatment,
such that the drug effect alone is shown.CIS-DDP BINDING TO BIOMOLECULES 263
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Figure 5 Cell survival of NHIK 3025 cells after treatment with
400 jM cis-DDP for 25 min at room temperature and one stan-
dard discharge treatment (consisting of five consecutive dis-
charges) given at different times after the end of drug treatment.
The dashed line (with S.E.) indicates the level of cell survival for
cells treated with cis-DDP alone (i.e. without electrical dis-
charges). The data were also used to calculate the 'effective
concentration' of cis-DDP (shown in Figure 6) for each observed
surviving fraction by the same procedure as described for Figures
1 and 2. In this case, however, survival curves obtained after
25 min exposure to increasing concentration of cis-DDP were
used.
activity, survivial curves were used to calculate effective cis-
DDP concentrations from data like those shown in Figure 5
in the same way as was described for the data presented in
Figures 1 and 2. In this case, however, we used survival
curves obtained after 25 min treatment with cis-DDP (not
shown) since this was the treatment duration used in the
corresponding electropermeabilisation experiments. In Figure
6 the effective concentration of cis-DDP is presented as
relative units, i.e. relative to the concentration of cis-DDP
which, if added to the cells for 25 min without electro-
permeabilisation, would give a similar cell survival. The data
presented in Figure 6 are from experiments performed at
room temperature and at 37TC.
Clearly the relative effective concentration of cis-DDP is
considerably lower than 1 if cells are electropermeabilised
immediately after the 25 min cis-DDP pulse (time 0), but
increases up to I if cells are electropermeabilised more than
30 (37°C) or 80 (room temperature) min after the cis-DDP
pulse. This finding supports our suggestion that subjecting
cells to electropermeabilisation immediately after the cis-
DDP pulse permits leakage of active cis-DDP out of the
cells, thus reducing the degree of cell damage. However,
within half an hour at 37°C and about 2-3 times that period
at room temperature, all intracellular cis-DDP may have
reacted with cellular constituents. The data therefore suggest
that the reaction rate of cis-DDP in the intracellular environ-
ment is about 2-3 times slower at room temperature as
compared to 37°C.
If this interpretation of the data in Figure 6 is correct, one
would also expect that analysis of cellular-bound Pt would
yield data similar to those shown in Figure 6. This was
investigated by measuring the amount of cell-associated Pt in
cells treated similarly as those shown in Figure 6. These
results are shown in Figure 7. A direct comparison shows
that the time course of the curves in Figure 7 is similar to
that of the curves in Figure 6.
Discussion
From previous studies it is known that binding of cis-DDP
to protein involves loss of cytotoxic activity (Takahashi et
al., 1985; Uchida et al., 1986; Cole & Wolf, 1980; Repta &
Long, 1980; Gormley et al., 1979; Holdener et al., 1982;
Hegedus et al., 1987). In the present studies we performed
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Figure 6 The relative concentration of biologically effective cis-
DDP as a function of the time between the end of a cis-DDP
pulse and electropermeabilisation of NHIK 3025 cells. The
effective concentration of cis-DDP was determined by the same
procedure as described for Figures 1 and 2, but with the use of
survival curves obtained after 25 min exposure to increasing con-
centrations of cis-DDP using survival data from experiments of
the type shown in Figure 5. The cells were treated with cis-DDP
for 25 min either at room temperature (400pM) or at 37°C
(130pM). Different symbols (with S.E.) represent different experi-
ments. The dashed line (with S.E.) shows the effect of treatment
with cis-DDP alone (without any electrical discharges).
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Figure 7 The relative amount of cell-associated Pt with NHIK
3025 cells treated for 25 min with 400ytM cis-DDP at room
temperature or with 130pM cis-DDP at 37°C, and thereafter
subjected to one standard discharge treatment at the indicated
times after ended drug treatment. Different symbols (with S.E.)
show different experiments. The dashed line (with S.E.) shows the
effect of treatment with cis-DDP alone (without any electrical
discharges).
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comparative measurements of the half-life of cis-DDP bind-
ing to extracellular as well as to intracellular macromolecules
by means of loss of cytotoxic activity.
In the extracellular environment binding to serum protein
is the major factor of importance concerning loss of cis-DDP
activity. This is strongly supported by the fact that the total
amount of ultrafilterable Pt decreases with a similar half-life
in E2a as the effective concentration of cis-DDP. Further-
more, there is no observed loss of cytotoxicity of cis-DDP
with time when the drug is dissolved in the absence of
proteins (Figure 3). The reaction rates obtained here support
findings reported earlier (Takahashi et al., 1985; Repta &
Long, 1980; LeRoy et al., 1979; van der Vijgh & Klein,
1986).
The binding of cis-DDP to serum proteins is also, as
expected, strongly temperature-dependent (Figure 3). Fur-
thermore, there is a clear correlation between the amount of
cell-associated Pt and drug cytotoxicity, indicating that the
protein-bound fraction of cis-DDP is impermeable to the
cells.
We have recently demonstrated only a marginal release of
Pt from these cells with time after a cis-DDP pulse (Melvik et
al., 1992), thus demonstrating only a slow drug efflux. It was
thus of interest to study if there could be an increased efflux
of drug when the cells were electropermeabilised after the
cis-DDP treatment. Control cells, i.e. cells not receiving drug
treatment, displayed little effect after being subjected to elect-
rical discharges except when repeated treatments were given
at room temperature (Figure 4). In this case the membrane
damage may have reached a critical level leading to complete
cell disruption (Gordon & Seglen, 1982; Zimmermann et al.,
1981; Melvik et al., 1986). The transiently increased
permeability of drugs was previously shown to be strongly
temperature-dependent (Gordon & Seglen, 1982; Benz &
Zimmermann, 1981), in accordance with the larger effect seen
at room temperature as compared to that at 37°C.
Electropermeabilisation may significantly protect cells
against the cytotoxicity of cis-DDP if cells are permeabilised
shortly after drug treatment (Figures 4 and 5). Thus, electro-
permeabilisation may increase the efflux of cytotoxic Pt
molecules, as it was shown earlier to increase the influx of
such molecules (Melvik et al., 1986; Dornish et al., 1986).
Our data, therefore, indicate that there is an intracellular
pool of active drug shortly after drug treatment. Further-
more, as there is a reduction in the cellular amount of Pt by
the electropermeabilisation procedure (Figures 6 and 7) our
data therefore suggest that drug efflux is inhibited by the cell
membrane. It is therefore also likely that cis-DDP does not
induce all damage immediately after entrance through the cell
membrane.
The use of reversible electropermeabilisation renders the
cell membrane permeable to small molecular weight com-
pounds only (Zimmermann et al., 1980; Gordon & Seglen,
1982; Riemann et al., 1975). Thus, cis-DDP bound to protein
and other large molecules will not be lost from the cells after
the electropermeabilisation procedure. This explains why no
further loss of Pt is seen when cells are electropermeabilised
after all drug has been bound intracellularly (Figure 6 and 7).
Furthermore, this finding is in accordance with the observa-
tion that no further increase in cell survival is seen when
repetitive treatments with electrical discharges are given
(Figure 4).
Comparison between the time course of the curves shown
in Figures 2 and 6 suggests that cis-DDP is bound more
rapidly in the intracellular than in the extracellular environ-
ment. While from Figure 2 the ti in serum at 37°C is more
than 2 h, Figure 6 shows that electropermeabilisation of cells
later than 30 min after drug treatment had no influence on
cell survival. This observation may be explained if one
assumes that all Pt is bound at this stage (corresponding to
ti e 11 min). Thus, the binding rate of cis-DDP is more than
ten times higher in the intracellular environment as compared
to human serum. Two factors may explain this difference:
Firstly, more reactive Pt-metabolites are expected to appear
in an environment having a low chloride concentration, as
inside of the cells, rather than a high one, as in the medium
(Chadwick et al., 1976; Szumiel & Nias, 1976; Segal & Le
Pecq, 1985; Dedon & Borch, 1987). Secondly, it is reasonable
to assume that the concentration of nucleophilic target
molecules is higher in the intracellular than in the extracel-
lular environment. The intracellular binding of cis-DDP may
include binding to particular nucleophilic proteins like metal-
lothioneins (Basu & Lazo, 1990), as well as to other com-
pounds like glutathione and methionine (Melvik & Pettersen,
1987; Dedon & Borch, 1987; Andrews et al., 1986; Sekiya et
al., 1989; Melvik et al., 1992; Anderson et al., 1990; Newman
et al., 1979).
The data of Figures 6 and 7 suggest that cis-DDP is bound
2-3 times more slowly at room temperature that at 37°C in
the intracellular environment (Figure 2). This is in accor-
dance with the respective reaction rates of cis-DDP binding
to serum components at the two temperatures as suggested
from the data in Figure 3. We have, however, previously
found a correlation between drug cytotoxicity and cellular
drug accumulation when comparing experiments performed
at room temperature and at 37°C (Melvik & Pettersen, 1988),
and a reduced uptake of cis-DDP through the cell membrane
at the former as compared to the latter temperature is
therefore probably responsible for this difference. Thus, it is
reasonable to believe that the reaction rate of cis-DDP
towards intracellular macromolecules is not the critical factor
for the reduced cytotoxicity observed by us and others at
hypo- as compared to normothermic temperatures (Melvik &
Pettersen, 1988; Herman, 1983). The cell membrane may
therefore be the critical factor for the cytotoxicity of cis-DDP
as the influx (Melvik et al., 1986) as well as the efflux (Melvik
et al., 1992) of cis-DDP, and other cytotoxic intermediates
through the plasma membrane is relatively slow compared to
the rate of binding to critical molecules (Figure 6). cis-DDP
molecules that are accumulated by the cells will therefore be
trapped and ultimately exert its cytotoxic damage indepen-
dent of the lowered temperature (room temperature). How-
ever, it is possible that the reduced reactivity of cis-DDP at
lower temperatures could reflect a reduced transport of cis-
DDP into the cells.
It is known that cis-DDP may act as a hypoxic radio-
sensitiser (Melvik & Pettersen, 1988; Overgaard & Khan,
1981; Stratford et al., 1980; Chibber et al., 1985; Douple &
Richmond, 1979). This effect is strongly temperature depen-
dent as we found a clear radiosensitising effect of cis-DDP
for NHIK 3025 cells irradiated under extremely hypoxic
conditions at 37°C, but not at room temperature (Melvik &
Pettersen, 1988). The data presented here therefore support
the idea discussed in our previous paper (Melvik & Pettersen,
1988) that it is the lower reactivity of cis-DDP towards
macromolecules that is critical for the temperature-dependent
hypoxic sensitisation, while it is the cell membrane that is
critical for the temperature-dependent cytotoxicity of cis-DPP
under hypothermic conditions. The underlying mechanisms
for these two temperature-dependent effects are, therefore,
fundamentally different.
The data presented here show that electropermeabilisation
may be used to demonstrate the significance of the cell
membrane as a barrier against the efflux as well as the influx
of cis-DDP, as presented earlier (Melvik et al., 1986; Dornish
et al., 1986). Our data are thus consistent with the presence
of a pool of active drug under and shortly after exposure to
cis-DDP. Furthermore, the electropermeabilisation method
has been used to establish data on the binding rate between
cis-DDP and cellular macromolecules, and confirms a much
faster binding rate between cis-DDP and macromolecules in
the intracellular as compared to the extracellular environ-
ment.
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